STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #837 by analyst upside · 2026-08-13
BEAM
Beam Therapeutics Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+95.3%
implied upside to consensus target
Current Price $26.71
Consensus Target $52.15
Bull Target $80.0
Bear Target $26.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
10
Hold
2
Sell
0
52-Week Low $15.6
52-Week High $38.26
YTD Return -1.6%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.69
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $156M
Profit Margin -55.4%
52-WEEK RANGE
52-Week Low $15.6
52-Week High $38.26
Current Price $26.71
Bear Target $26.0
Bull Target $80.0
● Now $26.71 ● Target $52.15
TRADING DATA
Avg Volume 2.2M
YTD Return -1.6%
Analyst Count 13
Consensus Buy
Upside to Target +95.3%
Last Updated 2026-08-13

ANALYST SUMMARY

Beam Therapeutics Inc. (BEAM) is currently trading at $26.71 with a Wall Street consensus price target of $52.15, implying potential upside of 95.3% over the next 12 months. 13 analysts currently cover BEAM, with a consensus rating of Buy - 85% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $80.0, while the most cautious has a target of $26.0.

BEAM operates in the Healthcare sector with a market capitalisation of $3B. The stock is down 1.6% year-to-date and is currently trading near the lower end of its 52-week range of $15.6 – $38.26.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BEAM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Bernstein - Reiterated
Outperform → Outperform 2026-05-13 Building track record
Citigroup - Reiterated
Buy → Buy 2026-03-26 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-02-25 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-02-25 Building track record
Canaccord Genuity ● Initiated
Buy 2026-02-20 Building track record
Bernstein - Reiterated
Outperform → Outperform 2026-01-21 Building track record
UBS ● Initiated
Neutral 2026-01-07 33% win rate (6 calls)
Evercore ISI Group ● Initiated
Outperform 2025-11-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
20/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →